ANNX Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -- compared to Annexon, Inc.'s net margin of -10571.43%. Annexon, Inc.'s return on equity of -84.23% beat AIM ImmunoTech's return on equity of -256.33%.

Annexon, Inc. has a consensus price target of $14.00, signalling upside risk potential of 181.69%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Annexon, Inc., analysts believe AIM ImmunoTech is more attractive than Annexon, Inc..

Annexon, Inc. has a beta of 1.204, which suggesting that the stock is 20.402% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Annexon, Inc.'s net income of -$54.9M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -- compared to Annexon, Inc.'s net margin of --. Annexon, Inc.'s return on equity of -84.23% beat CEL-SCI Corp.'s return on equity of -266.61%.

Annexon, Inc. has a consensus price target of $14.00, signalling upside risk potential of 181.69%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 568.24%. Given that CEL-SCI Corp. has higher upside potential than Annexon, Inc., analysts believe CEL-SCI Corp. is more attractive than Annexon, Inc..

Annexon, Inc. has a beta of 1.204, which suggesting that the stock is 20.402% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Annexon, Inc.'s net income of -$54.9M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Exelixis, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of 32.38%. Annexon, Inc.'s return on equity of -84.23% beat Exelixis, Inc.'s return on equity of 31.26%.

Annexon, Inc. has a consensus price target of $14.00, signalling upside risk potential of 181.69%. On the other hand Exelixis, Inc. has an analysts' consensus of $44.94 which suggests that it could grow by 9.94%. Given that Annexon, Inc. has higher upside potential than Exelixis, Inc., analysts believe Annexon, Inc. is more attractive than Exelixis, Inc..

Annexon, Inc. has a beta of 1.204, which suggesting that the stock is 20.402% more volatile than S&P 500. In comparison Exelixis, Inc. has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exelixis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. Exelixis, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than Exelixis, Inc. quarterly revenues of $597.8M. Annexon, Inc.'s net income of -$54.9M is lower than Exelixis, Inc.'s net income of $193.6M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while Exelixis, Inc.'s PE ratio is 17.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 5.11x for Exelixis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Annexon, Inc.'s net margin of -953.4%. Annexon, Inc.'s return on equity of -84.23% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Annexon, Inc. has a consensus price target of $14.00, signalling upside risk potential of 181.69%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1014.47%. Given that IGC Pharma, Inc. has higher upside potential than Annexon, Inc., analysts believe IGC Pharma, Inc. is more attractive than Annexon, Inc..

Annexon, Inc. has a beta of 1.204, which suggesting that the stock is 20.402% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Annexon, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annexon, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Annexon, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Annexon, Inc.'s net income of -$54.9M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Annexon, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annexon, Inc. is -- versus 26.09x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.